Genentech has executed another round of layoffs, affecting its Research and Early Development (gRED) group, without disclosing the total number of positions cut but describing it as "targeted adjustments" aligned with core therapeutic areas and portfolio priorities.
Three Genentech vice presidents—Vishva Dixit, M.D., Man-Wah Tan, Ph.D., and Todd McDevitt, Ph.D.—are among those laid off, as reported in internal communications and industry news.
The restructuring includes shutting down Genentech’s physiological chemistry and infectious disease teams, while the company continues hiring for select gRED roles deemed critical to advancing its portfolio and delivering transformative medicines.
This latest round follows a broader pattern of downsizing at Genentech and Roche, with more than 489 job cuts disclosed last year and additional workforce reductions ongoing in 2026.
Sources:
Genentech executes another round of layoffs, with 3 VPs axed
Genentech's Latest Layoffs Bring Total to Nearly 350 This Year
Genentech layoffs include elimination of infectious disease department
Genentech to lay off another 93 people, nearly half of them scientists
Genentech cut at least 489 jobs last year, new filing reveals
Genentech downsizes by 87 as priorities shift - PharmaLive
Bay Area biotech firm lays off dozens more scientists just months after 436-worker cut
Genentech cuts 143 jobs in strategic workforce adjustment | Angelo ...
Genentech announces another round of mass layoffs in South San Francisco
Genentech lays off 118, bringing 2025 total to 348 in San Francisco
Roche's Genentech Unit to Cut 223 Jobs in US - Eyewire News
Bay Area biotech giants Genentech and Sanofi to lay off more than 500 employees